Testing baricitinib to protect insulin-making cells in new type 1 diabetes
Tests baricitinib against placebo in people newly diagnosed with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Key facts
- Where
- Barakaldo, Barcelona, Esplugues de Llobregat, Madrid, Santander, Sevilla, and Valencia, SpainSee the 8 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and adults with type 1 diabetes diagnosed within the last 100 days who still make some insulin. It tests whether baricitinib helps keep that function.
- Age
- 1 year to 35 years
- Sex
- All sexes can join.
- Disease stage
- Type 1 diabetes newly diagnosed within 100 days before starting the study treatment, with signs of remaining beta-cell function (stimulated C-peptide ≥0.2 nmol/L (0.6 ng/mL) at screening).
- Biomarker or test result
- At least one diabetes-related autoantibody found at screening.
Main reasons for not taking part
- Any other type of diabetes, including gestational diabetes
- Uncontrolled high blood pressure
- Heart attack, heart disease, stroke or heart failure
- History or high risk of venous thromboembolism, lymphoproliferative disease or malignancy
- Current or recent clinically serious medical condition or infection
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 35 years old?
Source: NCT07222332, who can take part
Where in Spain
- Hospital Universitario de CrucesBarakaldo, SpainNo longer taking part
- Hospital Clinic de BarcelonaBarcelona, SpainNo longer taking part
- Hospital de la Santa Creu i Sant PauBarcelona, SpainNo longer taking part
- Hospital Sant Joan De Deu BarcelonaEsplugues de Llobregat, SpainNo longer taking part
- Hospital Universitario Ramón y CajalMadrid, SpainNo longer taking part
- Hospital Universitario Marqués de ValdecillaSantander, SpainNo longer taking part
- University Hospital Virgen Del Rocio S.L.Sevilla, SpainNo longer taking part
- Hospital Universitario Y Politecnico La FeValencia, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07222332EU 2025-522170-36-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.Read full original descriptionShow less
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Preserve Beta Cell Function in Participants Newly Diagnosed With Type 1 Diabetes Aged ≥1 to <36 Years
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
Inclusion: Have a new diagnosis of type 1 diabetes within 100 days prior to starting study intervention; Have at least one diabetes-related autoantibody found at screening; Show signs of remaining beta-cell function; stimulated (peak or 90 min) C-peptide ≥0.2 nmol/L (0.6 ng/mL) at screening; Weigh at least 8 kilograms (kg) (18 pounds) at screening.
Exclusion: Have any other type of diabetes including gestational; Have had a heart attack, heart disease, stroke, or heart failure; Have a history or high risk of venous thromboembolism, lymphoproliferative disease or malignancy; Have a current or recent clinically serious medical condition or infection; Have uncontrolled high blood pressure.